Related Experiment Videos
Moxalactam in the treatment of pediatric infections
Insights
Moxalactam disodium demonstrated clinical effectiveness in pediatric infections, showing comparable results to traditional antibiotics. This new oxacephalosporin is particularly promising for treating Haemophilus influenzae and Enterobacteriaceae infections in children.
Area of Science:
- Pediatric Infectious Diseases
- Pharmacology
- Clinical Microbiology
Background:
- Pediatric infections necessitate effective and safe antimicrobial agents.
- Oxacephalosporins represent a class of antibiotics with potential clinical utility.
- Evaluating novel antibiotics like moxalactam disodium is crucial for expanding treatment options.
Purpose of the Study:
- To assess the clinical efficacy and safety of moxalactam disodium in pediatric patients.
- To compare the effectiveness of moxalactam disodium against traditional antibiotics.
- To determine the in vitro susceptibility of common pediatric pathogens to moxalactam disodium.
Main Methods:
- Clinical trial involving 54 children with diverse pediatric infections.
- Administration of moxalactam disodium.
- In vitro sensitivity testing of isolated bacteria.
- Monitoring for clinical response and adverse events.
Main Results:
- Moxalactam treatment was effective in 53 out of 54 patients, with no recurrent infections observed.
- Clinical response rates were comparable to those of traditional antibiotics.
- In vitro studies showed sensitivity to moxalactam for most isolates, with exquisite sensitivity for Haemophilus influenzae; Pseudomonas aeruginosa was resistant.
- Adverse effects included thrombocytosis, elevated SGPT, eosinophilia, fever with rash, and neutropenia.
Conclusions:
- Moxalactam disodium shows promise as a useful antibiotic in pediatric care.
- It is particularly effective against infections caused by Haemophilus influenzae and Enterobacteriaceae.
- Further research is needed to define its role in treating infections caused by group B Streptococcus and Pseudomonas.
Abstract:
The clinical efficacy and safety of the new oxacephalosporin moxalactam disodium were evaluated in 54 children with a variety of pediatric infections. Except for a terminally ill neutropenic leukemic patient with pneumonia and sepsis due to Pseudomonas aeruginosa who died shortly after initiation of therapy, moxalactam treatment was effective in all patients. No recurrent infections were observed. The rate of clinical response to moxalactam appeared to be at least comparable to that of patients treated with traditional antibiotics. In vitro sensitivity testing demonstrated that all bacteria isolated except P aeruginosa were sensitive to moxalactam while Haemophilus influenzae was exquisitely sensitive. Side effects included thrombocytosis (five patients), transient SGPT elevations and eosinophilia (three each), fever with rash (one), and neutropenia (one). In one patient, superinfection with Streptococcus faecalis developed. We conclude that moxalactam may be a useful antibiotic in pediatrics, particularly for the treatment of infections due to H. influenzae and Enterobacteriaceae. Its role in infections caused by group B streptococcus and Pseudomonas awaits further studies.